Cargando…

Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells

Chimeric antigen receptor (CAR) T cells represent a potentially curative therapy for patients with advanced hematological cancers; however, uncertainties surround the cell-intrinsic fitness as well as the exhaustion that restrict the capacity of CAR-T. Decitabine (DAC), a DNA demethylating agent, ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	You, Liangshun, Han, Qingmei, Zhu, Li, Zhu, Yijing, Bao, Changqian, Yang, Chunmei, Lei, Wen, Qian, Wenbin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461863/ https://www.ncbi.nlm.nih.gov/pubmed/32973749 http://dx.doi.org/10.3389/fimmu.2020.01787

Ejemplares similares

Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma
por: Li, Sujun, et al.
Publicado: (2019)

Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells
por: Ruella, Marco, et al.
Publicado: (2015)

Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123
por: Morgan, Michael A., et al.
Publicado: (2021)

The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing
por: Riberdy, Janice M., et al.
Publicado: (2020)

CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
por: Tettamanti, Sarah, et al.
Publicado: (2014)

Downregulation of Mcl-1 synergizes the apoptotic response to combined treatment with cisplatin and a novel fiber chimeric oncolytic adenovirus
por: YOU, LIANGSHUN, et al.
Publicado: (2012)

The crosstalk between autophagic and endo-/exosomal pathways in antigen processing for MHC presentation in anticancer T cell immune responses
por: You, Liangshun, et al.
Publicado: (2017)

Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
por: Wang, Yao, et al.
Publicado: (2021)

Epigenetic synergy between decitabine and platinum derivatives
por: Qin, Taichun, et al.
Publicado: (2015)

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia
por: Ma, Gina, et al.
Publicado: (2018)

Global, Regional, and National Burden of Chronic Myeloid Leukemia, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017
por: Lin, Qingqing, et al.
Publicado: (2020)

SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt
por: Meng, Haitao, et al.
Publicado: (2013)

Decitabine: a historical review of the development of an epigenetic drug
por: de Vos, Dick, et al.
Publicado: (2005)

Chimeric Antigen Receptor T Cells Targeting CD19 and Ibrutinib for Chronic Lymphocytic Leukemia
por: Delgado, Julio, et al.
Publicado: (2019)

Phenotypic alteration of CD8(+) T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming
por: Wu, Jiazhu, et al.
Publicado: (2016)

MicroRNA‐mediated metabolic reprogramming of chimeric antigen receptor T cells
por: Rad, Seyed Mohammad Ali Hosseini, et al.
Publicado: (2022)

Mixed-phenotype acute leukemia treated with decitabine
por: Lee, Ji-Young, et al.
Publicado: (2016)

Decitabine Downregulates TIGAR to Induce Apoptosis and Autophagy in Myeloid Leukemia Cells
por: Li, Lanzhu, et al.
Publicado: (2021)

Development Of [(211)At]Astatine-Based Anti-CD123 Radioimmunotherapy For Acute Leukemias and Other CD123+ Malignancies
por: Laszlo, George S., et al.
Publicado: (2022)

Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies
por: Garcia-Prieto, Carlos A, et al.
Publicado: (2021)

Chronic lymphocytic leukemia presence impairs antigen-specific CD8(+) T-cell responses through epigenetic reprogramming towards short-lived effectors
por: Martens, Anne W. J., et al.
Publicado: (2023)

A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia
por: Yin, Jia, et al.
Publicado: (2021)

Epigenetic engineering for optimal chimeric antigen receptor T cell therapy
por: Ito, Yusuke, et al.
Publicado: (2022)

Immunoengineering via Chimeric Antigen Receptor-T Cell Therapy: Reprogramming Nanodrug Delivery
por: Katopodi, Theodora, et al.
Publicado: (2023)

Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity
por: Wang, Zhenzhen, et al.
Publicado: (2023)

Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
por: Kwag, Daehun, et al.
Publicado: (2022)

Decitabine in the treatment of acute myeloid leukemia in elderly patients
por: Malik, Priya, et al.
Publicado: (2014)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Anti-CD19 chimeric antigen receptor T-cell therapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia: Two case reports
por: Zhu, Yang-min, et al.
Publicado: (2016)

Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells
por: Abou Najem, Sonia, et al.
Publicado: (2019)

Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia
por: Zhang, Cheng, et al.
Publicado: (2022)

Epigenetic Anti‐Cancer Treatment With a Stabilized Carbocyclic Decitabine Analogue
por: Traube, Franziska R., et al.
Publicado: (2022)

Decitabine enhances the tumoricidal potential of TRAIL via the epigenetic regulation of death receptor 4 in gastric cancer
por: Li, Lin, et al.
Publicado: (2022)

The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells
por: Shi, Mingyue, et al.
Publicado: (2019)

The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
por: Santini, Valeria, et al.
Publicado: (2021)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Chimeric antigen receptor T-cell therapy in acute myeloid leukemia
por: Koedam, Jan, et al.
Publicado: (2022)

Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia
por: Tian, Shulan, et al.
Publicado: (2021)

Case report: Hashimoto’s thyroiditis after CD19 chimeric antigen receptor T-cell therapy
por: Chen, Panpan, et al.
Publicado: (2022)

Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation
por: Momparler, Richard L, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tgi55ldf65htsjrqr5924e4qn6